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Abstract
Background: Immunosuppression with calcineurin inhibitors (CNI) increases the risk of renal dysfunction after
orthotopic liver transplantation (OLT). Controlled trials have shown improvement of renal function in patients that
received delayed and/or reduced-dose CNI after OLT. Delaying immunosuppression with CNI in combination with
induction therapy does not increase the risk of acute rejection but reduces the incidence of acute renal
dysfunction. Based on this clinical data this study protocol was designed to assess the efficacy and safety of
calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation.
Methods/Design: A prospective therapeutic exploratory, non-placebo controlled, two stage monocenter trial in a
total of 29 liver transplant patients was designed to assess the safety and efficacy of de-novo CNI-free
immunosuppression with basiliximab, mycophenolate sodium, prednisolone and everolimus. The primary endpoint
is the rate of steroid resistant rejections. Secondary endpoints are the incidence of acute rejection, kidney function
(assessed by incidence and duration of renal replacement therapy, incidence of chronic renal failure, and
measurement glomerular filtration rate), liver allograft function (assessed by measurement of AST, ALT, total
bilirubin, AP, GGT), treatment failure, (i. e., re-introduction of CNI), incidence of adverse events, and mortality up to
one year after OLT.
Discussion: This prospective, two-stage, single-group pilot study represents an intermediate element of the
research chain. If the data of the phase II study corroborates safety of de-novo CNI-free immunosuppressive
regimen this should be confirmed in a randomized, prospective, controlled double-blinded clinical trial. The
exploratory data from this trial may then also facilitate the design (e. g. sample size calculation) of this phase III
trial.
Trial registration number: NCT00890253 (clinicaltrials.gov)
Background
Recipients of a liver allograft are at high risk of acute
and subsequently chronic renal dysfunction resulting in
a significantly increased risk of premature death [1,2].
After OLT more than 90% of patients receive an immu-
nosuppressive regimen based on calcineurin inhibitors
(CNI), i. e., cyclosporine A(CsA) or tacrolimus (TAC)
[3]. CNI cause renal arteriolopathy resulting in
histopathological and functional changes [4]. Hence,
nephrotoxicity associated with CNI mitigates renal func-
tion and contributes to the increased risk of end-stage
renal disease after OLT [5-7]. Strategies are needed to
minimize the incidence of renal impairment after OLT.
Pathophysiology of CNI-induced nephropathy
Despite major differences in the chemical structure,
both, TAC and CsA, seem to cause nephropathy charac-
terized by vasoconstriction of renal arterioles [4]. The
clinical manifestations of this acute renal dysfunction
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hypertension, hyperkalemia, tubular acidosis, increased
reabsorption of sodium and oliguria [8]. This acute form
of CNI toxicity may be reversed when CNI administra-
tion is reduced or withdrawn. In contrast, the chronic
form of CNI-induced nephrotoxicity is characterized not
only by renal vasoconstriction but also by the develop-
ment of structural damage, including arteriolopathy and
tubulointerstitial fibrosis, which is irreversible and may
lead to end-stage renal disease [4].
Immunosuppressive regimens to avoid CNI
Two main strategies to avoid the detrimental effects of
CNI on kidney function have been evaluated in clinical
trials. Long-term kidney damage may be attenuated by
reduction or even withdrawal of CNI some months after
OLT while maintaining adequate immunosuppression
by adding inosine monophosphate dehydrogenase
(IMPDH) inhibitors or mammalian target-of-rapamycin
(mTOR) inhibitors [9-13]. It has been shown that
regime change does not result in higher rejection rate
but improves kidney function.
However, not all patients seem to profit from this
strategy, possibly because irreversible kidney damage has
already taken place.
Alternatively, it has been shown in other studies that
administration of CNI may be delayed until the fifth
post-operative day (POD) or even later [14-17]. Ade-
quate immunosuppression in the early phase ofter
OLT was maintained with the perioperative adminis-
tration of interleukin 2-receptor (IL2R) antibodies (Ab)
or antithymocyte globuline (ATG). Neuberger et al.
conducted a randomized, prospective, open-label trial
in patients with good pretransplant kidney function in
which reduced dose tacrolimus (trough levels ≤ 8n g /
mL) was delayed until the fifth day post transplant in
combination with mycophenolate mofetil, corticoster-
oids and induction with daclizumab; the primary end-
point was change from baseline in estimated
glomerular filtration rate (eGFR) at 52 weeks [14].
They conclude that this regimen was associated with
less nephrotoxicity compared to therapy with stan-
dard-dose tacrolimus and corticosteroids without com-
promising efficacy or tolerability. The beneficial effect
of delaying CNI also been shown before in smaller
trials with a different study population or induction
therapy [15-17].
Thus avoiding acute CNI-associated kidney damage
ameliorates long-term kidney function even in patients
with good pretransplant kidney function. This effect
should even be more pronounced in patients with com-
promised pretransplant kidney function, a subgroup of
patients coming more and more into focus in the
MELD era.
Safety and efficacy of the investigational medicinal
products
Basiliximab, everolimus, and enteric-coated mycopheno-
late sodium (EC-MPS) are the investigational medicinal
products that will be evaluated in this clinical trial.
Basiliximab has been shown to reduce the incidence of
acute rejection with no clinically relevant safety or toler-
ability concerns [18,19]. Both IL2R antibodies, i. e., basi-
liximab and daclizumab, have also been shown to
prevent acute rejection even when CNIs are delayed for
five or more days after OLT [14,17]. Since daclizumab
has been withdrawn from the market we use basiliximab
as standard immunoprophylaxis in our transplant center
and in this study.
For maintenance immunosuppression the proposed
regimen will include the mTOR inhibitor everolimus.
Phase I and II trials of therapy with everolimus in de
novo liver transplant recipients implicate efficacy and
good tolerability of this immunosuppressant [20,21]. We
decided to use everolimus and not sirolimus because i)
dose adjustments are more convenient with the shorter
biological half-life of everolimus (28 hrs) compared to
sirolimus (61-72 hrs); ii) increased rates of hepatic artery
thrombosis and wound healing disturbances have been
observed in a trial involving sirolimus but not in trials
involving everolimus [20,21].
Nonetheless everolimus therapy will be delayed until
the 10th postoperative day for safety reasons. Concomi-
tantly the antimetabolite EC-MPS will be used instead
of the commonly used mycophenolate mofetil (MMF).
MMF may cause considerable gastro-intestinal adverse
reactions, e. g. diarrhea, and reduction or discontinua-
tion is not uncommon even in the immediate posttrans-
plant period. EC-MPS has been shown to cause less
adverse reactions und thus compliance with the study
protocol may be better.
EC-MPS will also be administered in a higher than
usual dose, i. e., 2160 mg/day instead of 1440 mg/day in
two doses, because van Gelder et al. suggested that
higher MPAexp osures in the early post-transplantation
period would be required in patients on reduced rather
than standard cyclosporine doses [22].
Study rationale
Generally, avoidance of CNIs improves kidney function
and does not result in higher rate of rejection when an
adequate level of immunosuppression is maintained, e.
g. by use of non-nephrotoxic immunosuppressive agents
such as mTOR-inhibitors and mycophenolate, and/or
concomitant interleukin-2 receptor blockade by induc-
tion with anti-CD25 antibodies [9-17,23,24]. However,
non of the mentioned studies investigated the effect of a
CNI-free de-novo regimen in patients that underwent
liver transplantation.
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protocol is designed to show primarily the safety of
CNI-free de-novo immunosuppression with basiliximab,
everolimus, EC-MPS, and corticosteroids in patients
after OLT with impaired pretransplant kidney function.
To determine whether this regimen has sufficient safety
and efficacy to warrant more extensive development and
to obtain preliminary data for sample size estimation
and planning of a phase III clinical trial this phase II
pilot study is designed as a prospective, non-rando-
mized, open-label study. If the CNI-free de-novo immu-
nosuppressive regimen gives adequate
immunosuppressive protection and is safe with regards
to toxicity, a phase III clinical trial will be conducted.
Methods & Design
Research was carried out in compliance with the Hel-
sinki Declaration. After completion of trial design and
approval by the competent authorities in Germany and
the European Union an ethics vote was obtained from
the ethics committee at the University Medical Center,
Göttingen, Germany before start of enrollment. Only
patients who meet the inclusion and exclusion criteria
(see Table 1) are considered for enrollment. After
enrollment patients will be followed-up for one year.
The schedule for all study related activities and data col-
lection is listed in Table 2.
Treatment
Immunosuppressive treatment (see Figure 1) will be
initiated at reperfusion of the graft starting with 500 mg
methylprednisolone and 20 mg basiliximab given
intravenously. The latter will be repeated on the 4th
post-operative day (POD).
Maintenance immunosuppression includes EC-MPS,
everolimus, and prednisolone. Since systemic exposure
of MPAmay be reduced in patients receiving immuno-
suppressive regimens with reduced dose CNI or without
CNI [22] EC-MPS will be given at an increased dose, i.
e., 1080 mg q12, starting within 24 hours after OLT.
Earliest, on day 10 after OLT everolimus will be intro-
duced with a loading dose of 5 mg/d. Thereafter a
dosage of 2 mg/d in two doses will be administered,
aiming at 24 hours trough levels for everolimus between
4a n d8n g / m L .S t e r o i d s( n o ni nvestigational medicinal
product) will be started on day 1 after transplantation
with 1 mg/kg body weight and will be tapered every
2d a y sf o r5m gt oad o s a g eo f2 0m ga n df o r2 . 5m g
every two days to 7.5 mg. Thereafter the dosage will be
reduced to 5 mg and 2.5 mg for 1 week each and elimi-
nated thereafter.
Additionally, every patient will receive Cytomegalo
virus (CMV) prophylaxis and prophylaxis against Pneu-
mocystis carinii infection during the first 3 months after
liver transplantation.
Objectives and endpoints
The primary objective of this pilot study is to evaluate
the safety and to investigate the preliminary efficacy of a
CNI-free immunosuppressive de-novo regimen in
patients with impaired renal function undergoing liver
transplantation. The primary endpoint was thus defined
as the incidence of biopsy proven steroid resistant acute
rejection(s) within the first 30 days.
Table 1 Criteria for inclusion and exclusion of patients.
Inclusion criteria Exclusion criteria
1. Patients undergoing primary liver transplantation. 1. Pregnant or nursing women.
2. Patients older than 18 years. 2. Patients with a psychological, familial, sociologic or geographic
condition potentially hampering compliance with the study protocol and
follow-up schedule.
3. Patients with a hepatorenal syndrome. 3. Patients under guardianship, i. e., individuals who are not able to freely
give their informed consent.
4. Female patients of childbearing potential willing to perform a highly
effective contraception during the study and 12 weeks after conclusion
of study participation.
†
4. Patients with pre-transplant renal replacement therapy > 14 days.
5. eGFR < 50 ml/min at the time point of transplantation. 5. Patients with a reason for renal impairment other than a hepatorenal
syndrome.
6. Serum creatinine levels > 1.5 mg/dL at the time-point of
transplantation.
6. Patients with a known hypersensitivity to any of the investigational
medicinal products.
7. Patients with thrombocytopenia (<50.000/nl), hypertriglyceridemia (>
350 mg/dl), or hypercholesterinemia (> 300 mg/dl), and patients with
signs of hepatic artery stenosis prior to initiation of therapy with
everolimus.
† A highly effective method of birth control is defined as those which result in a low failure rate (i.e. less than 1 per year) when used consistently and correctly
such as implants, injectables, combined oral contraceptives, hormonal intrauterine devices (IUDs), sexual abstinence or vasectomised partners in accordance to
CPMP/ICH/286/95.
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adverse reactions and renal function under the proposed
study regimen. Secondary endpoints will be evaluated
after in one interim analysis and after the end of the fol-
low-up period, i. e., one year, and include mortality, the
incidence of infection, treatment failure (defined as re-
introduction of CNI), wound-healing disturbances, hepa-
t i ca r t e r ys t e n o s e s ,a n dh e m a t o - l y m p h a t i cs i d ee f f e c t s .
Furthermore kidney damage will be assessed by the inci-
dence and length of renal replacement therapy and the
estimation of renal function using the Modification of
Diet in Renal Disease (MDRD) formula. Finally liver
allograft function will assessed by measurement of liver
enzymes, bile excretion, and coagulation assays.
All end-points will be compared to reference values of
CNI based immunosuppression obtained from a meta-
analysis [25].
Sample size calculation
The sample size calculation is based on the rate of steroid
resistant rejection after OLT. According to the pooled
estimate of a Cochrane meta-analysis the incidence of
steroid resistant rejection in patients with a CNI based
immunosuppressive regimen may be inferred as 12.61%
with a 95%-confidence interval of [6.36, 18.65] (estimated
by bootstrap methods) [25]. To minimize the sample size
for this therapeutic exploratory trial the study is designed
as a non-controlled, prospective, two-stage study. In this
two stage design [26] superiority of the safety or efficacy
rate to the required minimum or “uninteresting” rate p0
will be tested in stage I. If the treatment is inferior to p0
the trial will be halted and no further patients enrolled,
whereas if the treatment is superior to p0 stage II will be
entered. In stage II the rate will be compared to the
actual target rate p1. For the present trial p0 and p1 have
been fixed at 0.8 and 0.95 respectively. With error prob-
ability a =0 . 0 5a n dp o w e rb =0 . 2t h er e q u i r e ds a m p l e
sizes for stage I and II are n0 = 9 and n1 = 20 respectively.
The maximum success rates that corroborate inferiority
of the regimen to the fixed rates p0 and p1 have been cal-
culated as r0 =7a n dr0 + r1 = 26, meaning that if more
than 7 patients in stage I and 26 patients in stage II do
not experience a steroid resistant rejection the true
response is at least the target level p1 (see Figure 2).
Adverse events
All adverse events (AE) are recorded. Events related to
the initial diagnosis for liver transplantation, to the
transplantation procedure itself, or problems associated
with routine procedures after transplantation, i.e. liver
biopsy, are not to be noted as AE or serious adverse
event (SAE) unless the investigator deems the events to
be a cause of the study drug. All SAE potentially asso-
ciated with the application of study medication must be
documented and the sponsor has to be informed by the
principal investigator within 24 hours. The sponsor will
notify all concerned investigators, the Ethics Committee,
and competent authority of findings that could adversely
affect the health of subjects. AE will be analysed in an
interim analysis and at termination of the trial.
Quality assurance
The study is performed according to the principles of
the ICH-GCP guidelines and the ethical principles
Table 2 Schedule of study related activities and data
collection.
Study activity Day Month
-3-
0
12351 0 1 4 /
15
20/
21
25/
26
3 0361 2
Patient baseline characteristics and transplant data
Informed
consent
*
Medical history *
Physical
examin
*
Graft history *
Pregnancy test *
Safety parameters
Vital signs * **** * * * * * ** *
Blood
chemistry
†
* **** * * * * * ** *
Heamogram * **** * * * * * ** *
Coagulation
lab
†
* **** * * * * * ** *
MPAtrough
level
**** * * * * * ** *
EVL trough
level
*** * * * *
Ultrasound
‡ *** *
Adverse
events
**** * * * * * ** *
Rejection
¶ **** * * * * * ** *
Efficacy parameters
eGFR * **** * * * * * ** *
Rejection
|| **** * * * * * ** *
The chart indicates mandatory measurements and/or recordings by an
asterisk (green background color). Blood samples already taken in the routine
process at the planned time do not have to be taken twice.
† Mandatory laboratory measurements include: sodium, potassium, creatinine,
urea, alanine transaminase, aspartate transaminase, alkaline phosphatase, g-
glutamyl transferase, total bilirubin, lactate dehydrogenase, cholesterole,
triglycerides, activated partial thromboplastine time and Quick’s value.
‡ Additional examinations in case of pathological findings or indication.
¶ If laboratory measurements and/or clinical data indicate rejection the
attending transplant surgeon may decide to begin treatment with steroids. If
the rejection is clinically resistant to therapy with steroids a liver biopsy has to
be obtained. Only if there is histological evidence for steroid resistant
rejection it will be classified as such.
|| Rejection is a safety and efficacy parameter.
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Page 4 of 7Figure 1 Scheme of proposed reno-protective immunosuppressive regimen without CNI. Abbr.: EC-MPS, enteric-coated mycophenolate
sodium; POD, post-operative day; BW, body weight; q12h and q24h, every 12 or 24 hours.
Figure 2 Flow chart of the CILT study. Derived from an optimal two-stage design for a phase II clinical trial with the following parameters: p0
= 0.8, p1 = 0.95, error probability a = 0.05, and error probability b = 0.2. Abbr.: n, number of patients; r, maximum number of responders at
which H0 will not be rejected; H1, alternative hypothesis.
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Page 5 of 7according to the current revision of the Declaration of
Helsinki and local legal and regulatory requirements.
The trial is monitored by a contract research organiza-
tion according to standard operation procedures (SOP)
that are based on ICH-GCP guidelines. An independent
safety board monitors closely the proper conduct of the
trial and all SAE reports to ensure the safety of the sub-
jects during the course of the study.
Statistical analysis plan
The confirmatory analysis will be performed for the per-
protocol population. All statistical analyses will be
performed with a type I error a =0 . 0 5a n d ,w h e r e
appropriate, a non-inferiority margin of δ = -0.1 will be
assumed.
All rates will be tested in an approximate one sample
design test for non-inferiority [27] against reference
values obtained from a pooled meta-analysis of trials
with immunosuppressive regimen based on CNI [25].
Confidence intervals will be calculated by the method
of Agresti and Coull [28]. The only confirmatory analy-
sis will concern the primary endpoint; all other analyses
will be exploratory.
Continuous secondary end-points will be compared to
reference values with student’s T test unless there is
considerable evidence for a non-parametric distribution.
Event-time data, i. e., time to acute rejection, patient,
and graft survival will be estimated by the Kaplan-Meier
method.
Discussion
Long term kidney damage after OLT in patients with pre-
operative renal dysfunction is a growing problem in the
MELD era. CNI, which are the basis of most immunosup-
pressive regimens, may aggravate the damage and should
thus be avoided. Reducing or delaying CNI is safe and
reduces renal impairment. But it is not known if complete
abdication of CNI may increase the risk of rejection.
Before conducting a controlled, randomized, double-
blind phase III study to show efficacy of the drug regi-
men safety has to be ensured. Also effect size estimates
have to be obtained for for planing such a study, e. g.
for sample size calculation.
Hence, we designed this pilot study as a two-stage,
single-group, uncontrolled trial to assess the incidence
of steroid resistant rejection under the proposed treat-
ment. If the phase II study corroborates safety of de-
novo CNI-free immunosuppression the exploratory data
may serve as a fundament for planing and conducting a
randomized, prospective, controlled double-blinded clin-
ical trial to confirm the results.
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